Shots:   

• Following the US FDA approval, the EC has approved Eurneffy (2mg) for type I allergic reactions (anaphylaxis) in adults & children (≥30kg). It will be available in Q4’24 through a pharmaceutical company 

• The approval was supported by the results from a study, involving ~1200 administrations among >700 subjects, along with studies and peer-reviewed literature supporting these results 

• The study assessed PK/PD of Eureffy (2mg) under various conditions such as single and repeat dosing, self-administration, pediatric dosing & in nasal conditions like congestion and rhinorrhea due to allergens or infections like cold/flu 

Ref: ARS Pharmaceuticals | Image: ARS Pharmaceuticals

Related News:- ARS Pharmaceuticals’ neffy (Epinephrine Nasal Spray) Gains the US FDA’s Approval to Treat Type I Allergic Reactions

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com